



### Supplementary Figures




**Figure S1.** Doxorubicin treatment (600 nM) of non-tumor human kidney cell line HEK293T. Immunoblot analysis using the indicated antibodies is shown.


**A**




**B**



C




D




**Figure S2**

Immunoblot quantification of p19-caspase-3 (cCaspase-3), p89 PARP (cPARP), p62, LC3-II, pRIP1, RIP1 protein levels normalized to vinculin level in (A) Caov4, (B) HCT116, (C) U1810 cell lines and (D) pRIP1/RIP1 ratio presented by boxplot graphs. All values are in relative units. Each boxplot includes values from several different experiments (Exp).



**Figure S3.** Immunofluorescence analysis using anti-phospho-MLKL antibodies in Caov4, HCT116, and U1810 untreated cells. Cell nuclei were counterstained with Hoechst 33342 (blue). Scale bars: 10 μm.



**Figure S4.** Immunofluorescence analysis using anti-phospho-MLKL antibodies in Caov4 cells treated with the indicated agents. Green dots indicate phospho-MLKL. Cell nuclei were counterstained with Hoechst 33342 (blue). Scale bars: 10 mkM.